INTRODUCTION
Anti-Müllerian hormone (AMH), which is a member of the transforming growth factor-β superfamily, is secreted mainly by immature Sertoli cells at the time of sex differentiation in fetal life (i.e., at the end of the seventh gestation week). 1 The main role of fetal detected in 85% of patients with PMDS, with the causative genes unidentified in the remaining 15% of cases. Although autosomal recessive, autosomal dominant, and X-linked inheritance patterns have been reported in PMDS, most of the reported cases were isolated. [2] [3] [4] The AMH gene was mapped by Cohen-Hauguenaure in 1987. 5 Since then, more than 200 PMDS cases have been reported in the literature. [1] [2] [3] [4] 6 In this case report, we describe the clinical features of a case of PMDS type I with a novel AMH mutation.
MATERIAL AND METHODS

Case
The study was approved by the local ethics committee of Denizli State Hospital, Turkey. Written informed consent for the study was given by the parents of the patient.
A 4-month-old boy was admitted to the pediatric surgery clinic with the diagnosis of bilateral nonpalpable testes. There was second-degree consanguinity between his parents. A physical examination revealed a normal prepubertal sized penis (3.5 cm) and a normally developed scrotum. However, the gonads were bilaterally nonpalpable. The results of other systematic examinations were normal.
The serum levels of gonadotropins and testosterone were normal for the patient's age ( Laparoscopy revealed the presence of a rudimentary uterus at the midline and symmetrical fallopian tubes. The morphology of the gonadal structures was consistent with the testes being in a pseudo-ovarian position (i.e., the structures were attached to the fimbrial end of the fallopian tubes) ( Figure 1 ). An exploratory laparotomy/excision was planned for the patient. Staged bilateral orchidopexy (FowlerStephens technique) was performed and the Müllerian structures were removed.
A novel homozygous p.C526F (c.1577G>T) mutation on an evolutionary conserved amino acid was detected in the patient ( Figure 2 ). According to Poly- Endocrine evaluation Serum levels of FSH, LH, testosterone, and cortisol were determined using a chemiluminescent immunoassay (Architect; Abbott Diagnostics). AMH was measured by an electrochemiluminescence immunoassay (ECLIA) kit (Cobas 6000 e601; Roche Diagnostics). 17-hydroxyprogesterone was measured by RIA (PC-RIA.MAS Stratec, Germany).
Molecular analysis
DNA from the patient was isolated from peripheral blood leucocytes. A mutation analysis was then performed in the medical genetics department of Ege University, İzmir, Turkey. The AMH gene mutation analysis was performed by sequencing the coding exons of the gene. Genomic DNA was isolated from peripheral blood cells using standard techniques and PCR was performed. All PCR products were sequenced by the dye termination method using a DNA sequencing kit (Perkin-Elmer, CA, USA) and analyzed using an ABI Prism 3100 sequence analyzer (Applied Biosystems, CA, USA).
DISCUSSION
In a male human fetus, testosterone, dihydrotestosterone, and AMH are required for normal sex differentiation. AMH is produced by Sertoli cells by the end of the seventh gestational week and causes regression of the Müllerian ducts. Testosterone promotes the differentiation of the Wolffian ducts into the epididymis, vas deferens, and seminal vesicles. Dihydrotestosterone induces differentiation of external genitalia. 1 Due to a deficiency of AMH or the action of AMH, PMDS patients have both Wolffian and Müllerian ductal structures but normally developed external genitalia and Wolffian structures. 1, 2 In PMDS patients, remnants of the Müllerian duct (i.e., fallopian tubes, uterus, and the upper part of the vagina) are present in genotypically and phenotypically normal males. The main clinical characteristics are cryptorchidism and transverse testicular ectopia. 1, 2 PMDS can be classified into three anatomical types, depending on the location of the testes and Müllerian ductal structures. The most common type is the "male form", which is found in 80-90% of cases. In this type, at least one testis is present in the scrotum. In addition, the uterus and ipsilateral tubes are either present in the sac or can be drawn. The second (least common) type is the "female form", seen in 10-20% of cases. This type of PMDS is characterized by the presence of testes in the pseudo-ovarian position. The testes are attached to the fimbrial end of the fallopian tubes and the uterus is in the normal female pelvic position. In the third type, known as "transverse testicular ectopia", both testes are present on the same side, either in the inguinal canal or scrotum. 8 The clinical features in the present case were compatible with the second (female form) type of PMDS.
AMH gene mutations (PMDS type I) are responsible for approximately 45-52% of genetically proven PMDS cases. AMHR2 gene mutations (PMDS type II) are responsible for the remaining 40% of cases. 3, 4 Patients with AMH or AMHR2 gene mutations show no differences in the anatomical phenotype. However, patients with AMH gene defects have low or undetectable AMH levels, whereas those with AMHR mutations have normal or elevated levels of AMH. Laparoscopy is the preferred diagnostic procedure 1-4 To the best of our knowledge, as of June 2016 approximately 57 AMH mutations have been reported. 1, 6 The homozygous p.C526F (c.1577G>T) mutation detected in the present case is a novel mutation.
The risk of malignancy in an ectopic testis in a case of PMDS is similar to that in a cryptorchid testis in a healthy male. Germ cell tumors (embryonal carcinoma, seminomas, yolk sac tumors, and teratomas) are the most common types of tumors reported in the testes. 8, 9 Tumors of Müllerian ductal derivatives have also been reported. 10 The treatment of PMDS is surgical. There are some controversies regarding the management of PMDS patients. Bringing the testes down to a normal position is usually difficult in PMDS cases due to the shortness of the spermatic cord and the location of the vasa deferentia in the mesosalpinx or uterine wall. During surgery, the residual Müllerian ductal structures should be preserved to protect the vascular supply of the testis and vas deferens. However, malignant tumors of the Müllerian ducts have been reported. 8, 9, 11 Thus, some authors have proposed the adoption of a more aggressive surgical approach, which involves removing the Müllerian ductal structures. 8, 9, 11 To conclude, in all cases of bilateral cryptorchidism, the possibility of PMDS should be borne in mind. Genetic counselling should be considered in cases of parental consanguinity.
